Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Vaxcyte Inc (PCVX)

Vaxcyte Inc (PCVX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate GlobeNewswire - Wed Mar 18, 6:34PM CDT

Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data from...

PCVX : 55.38 (+2.59%)
Biotech research by Gorodenkoff via Shutterstock
Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock. Barchart - Mon Mar 2, 2:28PM CST

For growth-focused biotech investors, Vaxcyte is no longer just a science story.

PCVX : 55.38 (+2.59%)
STRO : 20.64 (-2.27%)
LZAGY : 59.1475 (-1.79%)
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update GlobeNewswire - Tue Feb 24, 3:05PM CST

Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety,...

PCVX : 55.38 (+2.59%)
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines GlobeNewswire - Wed Feb 11, 3:05PM CST

Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027  OPUS-1,...

PCVX : 55.38 (+2.59%)
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 GlobeNewswire - Tue Feb 10, 3:05PM CST

SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter...

PCVX : 55.38 (+2.59%)
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit GlobeNewswire - Thu Feb 5, 3:05PM CST

SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside...

PCVX : 55.38 (+2.59%)
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares GlobeNewswire - Mon Feb 2, 3:05PM CST

SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public...

PCVX : 55.38 (+2.59%)
Vaxcyte Announces Pricing of $550 Million Public Offering GlobeNewswire - Thu Jan 29, 10:33PM CST

SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of common...

PCVX : 55.38 (+2.59%)
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants GlobeNewswire - Thu Jan 29, 3:06PM CST

SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering...

PCVX : 55.38 (+2.59%)
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine GlobeNewswire - Thu Jan 22, 4:00PM CST

VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study...

PCVX : 55.38 (+2.59%)

Barchart Exclusives

IWM’s Surge in Unusual Options Activity Signals Opportunity — Here’s a Covered Strangle With a Twist Barchart - 12 minutes ago
The iShares Russell 2000 ETF’s options volume on Thursday was 20% higher than its 30-day average. However, it was the ETF’s unusual options activity that stood out, with 3 of the top 5 Vol/OI ratios. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.